Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 2
2011 3
2012 2
2013 1
2014 2
2015 1
2016 3
2017 2
2018 3
2020 3
2021 4
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
Sadoff J, De Paepe E, DeVincenzo J, Gymnopoulou E, Menten J, Murray B, Rosemary Bastian A, Vandebosch A, Haazen W, Noulin N, Comeaux C, Heijnen E, Eze K, Gilbert A, Lambkin-Williams R, Schuitemaker H, Callendret B. Sadoff J, et al. Among authors: callendret b. J Infect Dis. 2022 Aug 26;226(3):396-406. doi: 10.1093/infdis/jiab003. J Infect Dis. 2022. PMID: 33400792 Free PMC article. Clinical Trial.
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K, Bastian AR, Feldman RA, Omoruyi E, de Paepe E, Hendriks J, van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, Sadoff J, Callendret B. Williams K, et al. Among authors: callendret b. J Infect Dis. 2020 Aug 17;222(6):979-988. doi: 10.1093/infdis/jiaa193. J Infect Dis. 2020. PMID: 32320465 Clinical Trial.
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
Saeland E, van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, Vaneman C, Tettero L, Serroyen J, Schuitemaker H, Callendret B, Langedijk JPM, Zahn RC. Saeland E, et al. Among authors: callendret b. Vaccine. 2022 Feb 7;40(6):934-944. doi: 10.1016/j.vaccine.2021.12.043. Epub 2021 Dec 29. Vaccine. 2022. PMID: 34973849 Free article.
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.
Roozendaal R, Hendriks J, van Effelterre T, Spiessens B, Dekking L, Solforosi L, Czapska-Casey D, Bockstal V, Stoop J, Splinter D, Janssen S, Baelen BV, Verbruggen N, Serroyen J, Dekeyster E, Volkmann A, Wollmann Y, Carrion R Jr, Giavedoni LD, Robinson C, Leyssen M, Douoguih M, Luhn K, Pau MG, Sadoff J, Vandebosch A, Schuitemaker H, Zahn R, Callendret B. Roozendaal R, et al. Among authors: callendret b. NPJ Vaccines. 2020 Dec 17;5(1):112. doi: 10.1038/s41541-020-00261-9. NPJ Vaccines. 2020. PMID: 33335092 Free PMC article.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop JN, Roozendaal R, Van Effelterre T, Gaddah A, Van Roey GA, Solforosi L, Zahn R, Callendret B, Hendriks J, Luhn K, Douoguih M, Schuitemaker H, Van Hoof J. Bockstal V, et al. Among authors: callendret b. NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z. NPJ Vaccines. 2022. PMID: 36450746 Free PMC article.
Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries.
Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, Comeaux C, Tran TMP, Weber K. Nguyen-Van-Tam JS, et al. Among authors: callendret b. Eur Respir Rev. 2022 Nov 15;31(166):220105. doi: 10.1183/16000617.0105-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36384703 Free article. Review.
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R. Callendret B, et al. PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018. PLoS One. 2018. PMID: 29689118 Free PMC article.
32 results